Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Clinical Study on the Efficacy and Safety of the Novel Oncolytic Virus Ad-TD-nsIL12 Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma

NCT07472790 is registered in ClinicalTrials.gov with Beijing Bio-Targeting Therapeutics Technology Co., Ltd as lead sponsor.

NCT NCT07472790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07472790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Clinical Study on the Efficacy and Safety of the Novel Oncolytic Virus Ad-TD-nsIL12 Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
Lead sponsor
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
April 30, 2028
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade glioma